The effect of topical ketorolac tromethamine on macular thickening after phacoemulsification in diabetic patients

BMC Ophthalmology

Research

Kourosh Sheibani¹  Razieh Bahreini²  Hamideh Sabbaghi³  Mehdi Emamverdi⁴  Bahareh Kheiri⁴  Hossein Mohammad-Rabei⁵  Alireza Ramezani⁵  Saeed Karimi⁵  Homayoun Nikkhah⁵  Mehdi Yaseri⁶ 

[1] Basir Eye Health Research Center, Tehran, Iran;Department of Optometry, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Opposite to Bou-Ali Hospital, Damavand Ave., Tehran, Iran;Ophthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran;Department of Optometry, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Opposite to Bou-Ali Hospital, Damavand Ave., Tehran, Iran;Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran;Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran;Department of Ophthalmology, Torfe Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran;School of Public Health and Public Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran;

关键词: Phacoemulsification;    Ketorolac Tromethamine;    Central Retinal Thickness;    Diabetes;   

DOI  :  10.1186/s12886-023-03077-y

 received in 2023-02-27, accepted in 2023-07-12,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundTo determine the effect of ketorolac tromethamine 0.5% in preventing post-phacoemulsification macular thickening. This randomized clinical trial. patients randomized 1:1 to receive either topical ketorolac three times a day or a placebo.MethodsA total of 101 eyes of 101 diabetic patients who were scheduled for phacoemulsification and had normal macular contour and thickness enrolled consecutively. The topical ketorolac and placebo were prescribed on the day before surgery and continued up to 4 weeks after surgery. Patients with proliferative diabetic retinopathy, a history of intravitreal injection in less than three months, a history of macular photocoagulation in less than 6 months, and any other concomitant ocular pathologies were excluded. Central macular thickness (CMT) and best corrected visual acuity (BCVA) was recorded in the follow-ups of 6, 12, and 24 weeks after the surgery and compared with the controls.Results49 eyes in the case group and 52 eyes in the control group were analyzed. Mean BCVA was significantly improved in both groups at all follow-ups (P < 0.001 for all). There was no statistically significant difference regarding the BCVA in different time points except week 12 (P = 0.028) among the study group. In the case and control groups, CMT was increased at all follow-ups (P < 0.05). There was no statistically significant difference when comparing the two groups regarding the mean of CMT at any time point postoperatively (P > 0.05 for all).ConclusionBased on our findings, topical ketorolac tromethamine 0.5% is not effective in the prevention of post-phacoemulsification macular thickening in diabetic patients.Trail registrationThe study protocol was registered into www.clinicaltrial.gov with the RCT registration number NCT03551808. (2018/06/11 )Clinical trial registration numberNCT03551808.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

42004_2023_944_Article_IEq9.gif